Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Auris Initiates Second Phase III For Pipeline-Leading Hearing Loss Drug

Executive Summary

Auris Medical Holding AG has moved its hearing loss therapeutic, AM-111, into a second Phase III study, making it the most advanced drug in the pipeline for the treatment of sudden deafness, according to Biomedtracker.

You may also be interested in...

Auris Sees A Window To Treat Profound Hearing Loss Despite Phase III Failure

The HEALOS trial testing AM-111 in sudden deafness did not meet the primary efficacy endpoint, but a subpopulation of patients with the worst hearing loss did show a statistically significant benefit.

Auris' Outlook Bleak In Tinnitus After Failure Of Initial Phase III Trial

The Swiss biotech still holds out hope that its NMDA antagonist Keyzilen will hit its primary endpoint in a European Phase III study in acute tinnitus, but a largely US-based first Phase III trial missed both co-primary endpoints.

Reaching Factor Of 10 Impact On Health Care Innovation

Funded by the UK government, The Rosalind Franklin Institute works with industrial and academic partners from across the UK to foster interdisciplinary research with “real impact.” Leaders from the growing institute talk to In Vivo about validating its success and what it means to seek truly ground-breaking innovation in 2021. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts